Choreo LLC Decreases Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Choreo LLC trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 17.5% during the fourth quarter, Holdings Channel reports. The fund owned 40,693 shares of the company’s stock after selling 8,622 shares during the period. Choreo LLC’s holdings in Elanco Animal Health were worth $481,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its stake in Elanco Animal Health by 76.6% in the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock valued at $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. State Street Corp raised its stake in shares of Elanco Animal Health by 2.6% in the third quarter. State Street Corp now owns 9,912,693 shares of the company’s stock valued at $145,617,000 after buying an additional 255,084 shares during the period. Geode Capital Management LLC lifted its position in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after buying an additional 65,303 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Elanco Animal Health by 6.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock worth $93,803,000 after acquiring an additional 394,921 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after acquiring an additional 646,522 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

ELAN has been the topic of several recent research reports. Stifel Nicolaus dropped their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. Morgan Stanley reduced their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 29th. UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Barclays lifted their price target on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $16.29.

Elanco Animal Health Stock Down 0.5 %

Shares of NYSE:ELAN opened at $11.42 on Wednesday. The firm has a fifty day moving average price of $11.99 and a two-hundred day moving average price of $13.18. The company has a market cap of $5.65 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.69 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a one year low of $11.11 and a one year high of $18.80.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.